1. Academic Validation
  2. c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

  • Cell Death Dis. 2020 Sep 15;11(9):760. doi: 10.1038/s41419-020-02980-2.
Wenfei Ji  # 1 Wenwen Zhang  # 2 Xin Wang 3 Yaqin Shi 3 Fang Yang 3 Hui Xie 4 Wenbin Zhou 4 Shui Wang 4 Xiaoxiang Guan 5 6
Affiliations

Affiliations

  • 1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • 2 Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  • 3 Medical School of Nanjing University, Nanjing, China.
  • 4 Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • 5 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [email protected].
  • 6 Medical School of Nanjing University, Nanjing, China. [email protected].
  • # Contributed equally.
Abstract

Palbociclib, a CDK4/6 inhibitor, has been granted accelerated approval by US FDA for hormone receptor-positive HER2-negative metastatic breast Cancer. To determine potential biomarkers of palbociclib sensitivity to assist in patient selection and clinical development, we investigated the effects of palbociclib in a panel of molecularly characterized breast Cancer cell lines. We quantified palbociclib sensitivity and c-Myc expression in 11 breast Cancer cell lines, 124 breast Cancer samples, and The Cancer Genome Atlas database. We found non-TNBC subtypes were more sensitive to palbociclib than TNBC. Activation of c-Myc led to differential palbociclib sensitivities, and further inhibition of c-Myc enhanced palbociclib sensitivity. Moreover, we identified for the first time a c-Myc/miR-29b-3p/CDK6 axis in breast Cancer that could be responsible for c-myc-induced palbociclib insensitivity, in which c-Myc activation resulted in downregulation of miR-29b-3p, further activated CDK6 and inhibited cell-cycle arrest at G1 phase. Moreover, downregulated (inactived) c-myc-induced oncogenic addiction could increase palbociclib efficacy, using both Xenograft model and patient-derived tumor xenograft (PDTX) model. Our finding extends the concept of combined blockade of the CDK4/6 and c-Myc signaling pathways to increase palbociclib sensitivity, making c-Myc a promising biomarker for palbociclib sensitivity in breast Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-50767
    99.96%, CDK4/6 Inhibitor
    CDK
  • HY-100669
    99.21%, Myc-Max Inhibitor